Phase I/II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating irresectable liver metastases

Trial Profile

Phase I/II trial with melphalan for percutaneous chemosaturation (CS-PHP-Mephalan) in treating irresectable liver metastases

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Melphalan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms CS-IHP-Melfalan
  • Most Recent Events

    • 30 Sep 2015 According to a Delcath System media release, data were presented at the Cardiovascular and Interventional Radiology Society (CIRSE) annual meeting.
    • 30 Sep 2015 Results published in a Declath Systems media release.
    • 15 Sep 2014 Five patients have been enrolled and treated to date, according a Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top